Upexi director granted 100,000 restricted shares

Salkind Gene reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/20/2026 - 05:36 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Salkind Gene reported acquisition or exercise transactions in this Form 4 filing.

Upexi, Inc. director Gene Salkind received a grant of 100,000 shares of restricted common stock under the company’s 2019 Incentive Stock Plan, as amended. The award vests in four equal quarterly installments, with full vesting on July 1, 2027, subject to continued service. After this grant, Salkind directly holds 318,750 common shares.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Salkind Gene

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	100,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 318,750 shares (Direct)

Holdings Before and After: Common Stock, 218,750 to 318,750 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock granted pursuant to the Issuer's 2019 Incentive Stock Plan, as amended, that vests in four equal quarterly installments, with full vesting on July 1, 2027, subject to continued service.

Key Figures

Restricted stock grant: 100000.0000 shares Grant price: $0.0000 per share Shares following transaction: 318750.0000 shares +1 more

4 metrics

Restricted stock grant 100000.0000 shares Grant of restricted common stock to director Gene Salkind

Grant price $0.0000 per share Reported transaction price per share for the restricted stock award

Shares following transaction 318750.0000 shares Total common shares directly held by Gene Salkind after the grant

Full vesting date July 1, 2027 Restricted stock vests in four equal quarterly installments with full vesting on this date

Key Terms

restricted stock, 2019 Incentive Stock Plan, four equal quarterly installments, continued service

4 terms

restricted stock financial

"Represents restricted stock granted pursuant to the Issuer's 2019"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2019 Incentive Stock Plan financial

"granted pursuant to the Issuer's 2019 Incentive Stock Plan, as"

four equal quarterly installments financial

"that vests in four equal quarterly installments, with full"

continued service financial

"with full vesting on July 1, 2027, subject to continued service."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UPXI report for Gene Salkind?

Upexi reported that director Gene Salkind received a grant of 100,000 restricted shares of common stock. The award is compensation, granted at $0.0000 per share, and increases his direct ownership to 318,750 Upexi common shares.

How many Upexi (UPXI) shares does Gene Salkind now hold?

Following the reported grant, Gene Salkind directly holds 318,750 Upexi common shares. This total reflects the addition of 100,000 restricted shares awarded under Upexi’s 2019 Incentive Stock Plan, as amended, as disclosed in the insider ownership table.

When do Gene Salkind's UPXI restricted shares fully vest?

Gene Salkind’s restricted Upexi shares fully vest on July 1, 2027. The award vests in four equal quarterly installments leading up to that date, and vesting is conditioned on his continued service to the company during the vesting period.

Was the UPXI insider grant made under a Rule 10b5-1 plan?

The filing indicates the Rule 10b5-1 checkbox was not marked, so the reported grant was not disclosed as made under a Rule 10b5-1 trading plan. It is characterized as a compensation-related grant or award, not a pre-planned trading transaction.

What plan governs Gene Salkind's new UPXI restricted stock award?

The new restricted stock award to Gene Salkind is granted under Upexi’s 2019 Incentive Stock Plan, as amended. The footnote states the shares are restricted stock subject to this plan’s terms, including quarterly vesting and the requirement for continued service until full vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salkind Gene

(Last) (First) (Middle)

3030 N ROCKY POINT DRIVE

STE. 420

(Street)

TAMPA FLORIDA 33607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UPEXI, INC. [ UPXI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/03/2026		A		100,000(1)	A	$0	318,750	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted pursuant to the Issuer's 2019 Incentive Stock Plan, as amended, that vests in four equal quarterly installments, with full vesting on July 1, 2027, subject to continued service.

	/s/ Gene Salkind	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)